Product Description
Mechanisms of Action: VEGF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Spain | Sweden | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: AVEO
Company Location: BOSTON MA 02108
Company CEO: Michael Bailey
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, Chile, Czech Republic, France, Germany, Italy, Mexico, Poland, Portugal, Spain, United Kingdom, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Renal Cell Carcinoma
Phase 2: Adenocarcinoma|Bile Duct Cancer|Breast Cancer|Cholangiocarcinoma|Gallbladder Cancer|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Sarcoma|Soft Tissue Cancer|Vulvar Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| UF-STO-ETG-003 | P2 |
Recruiting |
Adenocarcinoma|Neuroendocrine Carcinoma|Gallbladder Cancer|Bile Duct Cancer|Ovarian Cancer|Sarcoma|Soft Tissue Cancer|Prostate Cancer|Vulvar Cancer|Cholangiocarcinoma|Neuroendocrine Tumors|Pancreatic Cancer|Breast Cancer |
2025-06-01 |
12% |
2024-09-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| AV-951-20-304 | P3 |
Active, not recruiting |
Renal Cell Carcinoma |
2025-07-31 |
2025-05-02 |
Treatments |
|
| NCI-2023-07385 | P2 |
Recruiting |
Renal Cell Carcinoma |
2026-11-01 |
12% |
2024-01-11 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| 2021-000050-26 | P3 |
Active, not recruiting |
Renal Cell Carcinoma |
2025-09-30 |
2025-05-06 |
Treatments |
|
| TiNivo-2 | P3 |
Active, not recruiting |
Renal Cell Carcinoma |
2024-04-01 |
35% |
2024-10-25 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/03/2025 |
News Article |
AVEO Oncology, an LG Chem company, Presents Three Posters at ASCO 2025 Annual Meeting |
|
05/07/2025 |
News Article |
City of Hope Research on Breast Cancer, Supportive Care, Kidney Cancer and More to Be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting |
|
04/28/2025 |
News Article |
AVEO Oncology, an LG Chem company, Announces Three Poster Presentations at ASCO 2025 Annual Meeting |
|
02/18/2025 |
News Article |
AVEO Oncology, an LG Chem company, Presents Two Posters for Tivozanib at the 2025 ASCO GU Meeting |